

# Dose-to-medium vs. dose-to-water: Dosimetric evaluation of head and neck VMAT cases using Monaco treatment planning system

Saravana Kumar Gopal<sup>1,2</sup>, Purendra Chandra Dash<sup>2</sup>

<sup>1</sup>CIMS Radiation Centre, CIMS Hospitals. Pvt. Ltd, Ahmedabad, India

<sup>2</sup>Department of Physics, Siksha 'O' Anusandhan University, Bhubaneswar, India

Received June 3, 2016; Revised December 20, 2016; Accepted December 22, 2016; Published Online December 28, 2016

## Original Article

### Abstract

**Purpose:** In this paper, we evaluate the dosimetric differences between absorbed dose to water and absorbed dose to medium in Monte Carlo (MC)-based calculations used for radiation therapy treatment plans. **Methods:** Thirty-four treated Head and Neck simultaneously integrated boost cases were analyzed retrospectively. All of them were planned by Monaco treatment planning system (TPS), calculated and reviewed on absorbed dose to medium ( $D_m$ ) calculations and treated in Elekta Versa HD LINAC. Absorbed dose to medium  $D_m$  was converted to absorbed dose to water  $D_w$  in Monaco treatment planning system using the procedure based on stopping power ratios and the Bragg-Gray cavity theory. Dosimetric parameters were then compared and analyzed with respect to absorbed dose to medium ( $D_m$ ) calculations for multiple planning target volumes (PTVs) and critical organs such as brainstem, spinal cord, left and right lens, left and right parotids, larynx, left and right middle ear and lips. **Results:** It was found that mean and minimum  $D_w$  (i.e.  $D_{w\text{ mean}}$  and  $D_{w\text{ min}}$ ) of organs at risk did not differ much (hardly differing by 0.8-2%) with respect to those of the absorbed dose to medium. However maximum  $D_w$  (i.e.  $D_{w\text{ max}}$ ) in case of lips, left and right middle ear were found to differ more than 4% with respect to  $D_{m\text{ max}}$ . For serial organs brainstem and spinal cord, maximum dose  $D_{w\text{ max}}$  were found to vary around 1% and 2%, respectively, with respect to absorbed dose to medium dose calculation. In case of PTVs, the mean percentages variation of  $D_{w\text{ min}}$  and  $D_{w\text{ mean}}$  were found to be less than 1 %, although the variation of maximum  $D_w$  was found to be high around 5-7% with respect to that of  $D_m$ . **Conclusion:** The comparative analysis of dosimetric parameters in the present study shows that the selection of either  $D_m$  or  $D_w$  in Monaco planning system is less likely to produce any significant clinical effect in tumor control and to the damage of organs at risk.

**Keywords:** Monte Carlo based calculation, Dose-to-water, Dose-to-medium, Radiotherapy, Treatment planning system

## 1. Introduction

Monte Carlo (MC)- based calculations algorithms are considered most accurate over the conventional and even more recent model- based algorithms used in the radiation therapy treatment plans<sup>1-7</sup>. Despite its proven accuracy, MC-based-planning has been clinically possible only recently due to the improvement in both computer hardware capabilities and improved MC codes. American association of Physicists in Medicine (AAPM) Task Group-105 (TG-105) has discussed critically the issues associated with clinical implementation of Monte- Carlo-based photon and electron external beam treatment planning<sup>1</sup>. One of the

issues which remains debatable is whether one should use absorbed dose-to-water  $D_w$  or absorbed dose-to-medium  $D_m$  for dose calculations, prescription and evaluation when using MC based treatment planning system (TPS).

Conventional dose calculations for photon beam radiation therapy typically report the absorbed dose-to-water  $D_w$ <sup>1,6,8</sup>. This is due to the fact that historically clinical experiences are derived based on  $D_w$ . Furthermore, the doses reported in clinical trials and hence the therapeutic and normal tissue tolerance doses

**Corresponding author:** Saravana Kumar Gopal; CIMS Radiation Centre, CIMS Hospitals. Pvt. Ltd, Ahmedabad, India.

**Cite this article as:** Gopal SK, Dash PC. Dose-to-medium vs. dose-to-water: Dosimetric evaluation of head and neck VMAT cases using Monaco treatment planning system. *Int J Cancer Ther Oncol.* 2016; 4(4):4416. DOI:10.14319/ijcto.44.16

are based on  $D_w$ . The accelerator and ionization chamber calibration protocols are also based on  $D_w$ <sup>9</sup>. The absolute dose measurements, input data used for TPS commissioning are generally dose profiles and output factors measured in water phantoms and specified in terms of absorbed dose to water  $D_w$ . However, MC based algorithms perform calculations for absorbed dose to medium instead of absorbed dose to water. Since the particle transport simulations occur in materials representation of patient media, the absorbed dose is specified to the patient medium  $D_m$ <sup>10-16</sup>. For comparison of results and their clinical significance in radiation therapy treatment plans,  $D_m$  is converted to  $D_w$  by the procedure developed by Siebers *et al.*<sup>8</sup> using stopping power ratios, based upon the Bragg-Gray cavity theory for MC-based calculations. For megavolt-age photon beams, the difference between  $D_w$  and  $D_m$  for tissues with densities near 1.0 g/cm<sup>3</sup> is small (1–2%). However, for higher density materials, such as cortical bone, the difference can be as large as 15% since the stopping powers of water and that of higher-density materials differ more significantly<sup>1,8</sup>. Therefore, there is a systematic difference between the dose computed using conventional analytical algorithms and MC simulation. Any significant differences between  $D_w$  and  $D_m$  might lead to the change of dose prescriptions in order to maintain consistent radio therapy outcomes<sup>8,17</sup>. A clinical decision has to be made during radiotherapy treatment planning as to whether one should prescribe the dose using  $D_m$  or the converted  $D_w$ <sup>18</sup>. Several studies have reported dosimetric difference between  $D_w$  and  $D_m$  based plans for different clinical cases in various planning systems<sup>19,20</sup>. Dogan *et al.*<sup>21</sup> demonstrated that converting  $D_m$  to  $D_w$  in MC- calculated IMRT plans introduces a systematic error of up to 5.8% for head and neck tumors and 8.0% for prostate cases. However, similar studies for head and neck VMAT cases based on MC-calculated treatment plans using Monaco TPS have not yet been reported. In the present study, we evaluate the dosimetric difference between absorbed dose-to-water and absorbed dose-to-medium in the MC-based dose calculation method in the radiation therapy treatment planning for head & neck VMAT cases and analyze its clinical significance.

## 2. Methods and Materials

### 2.1. Patient Selection

A total of 34 head and neck cases with multiple PTVs of different prescriptions were taken for analysis. Out of 34 cases, 28 cases had 3 PTVs and remaining 6 cases had 2 PTVs. Patient total prescription details are given in the Table 1. All patients were treated using Elekta Versa HD Linear Accelerator (Elekta Ltd, Crawley, UK) which is equipped with Agility Beam limiting Device. Mosaic

version (IMPAC Medical systems Inc, Sunnyvale, USA) was used as record and verifying system.

**Table 1:** Prescription details of patient cases

No of Patients	34
Case	Head & Neck VMAT
3 PTVs cases	28
2 PTVs cases	6
PTV I	6930 cGy – 34 cases
PTV II(Total - 34Cases)	6600 cGy- 12 cases;5940 cGy- 4cases 6300 cGy- 13cases; 6434 cGy- 5 cases
PTV III(Total - 28Cases)	5940 cGy- 5 cases; 5610 cGy-16 cases 5775 cGy- 4cases; 5710 cGy- 3 cases


### 2.2. Treatment Planning

3D CT scans of slice thickness of 3 mm were acquired using Philips Brilliance CT scanner with patient in supine position. Thermoplastic moulds are used for immobilization of patients. Monaco treatment planning system (Elekta, Crawley, UK) version 5.0 was used for VMAT planning using 6MV photon beams.

Monaco treatment planning system uses the Monte Carlo dose calculation algorithm for VMAT dose calculations. The system provides options either to use absorbed dose to water  $D_w$  or absorbed dose to medium  $D_m$  mode for treatment dose calculation, prescription and evaluation. Here we used the Monaco TPS in which we perform MC-based calculation for absorbed dose to medium  $D_m$ . Then we evaluated the absorbed dose to water  $D_w$  in Monaco TPS from the MC calculated  $D_m$  using stopping power ratio based on Bragg Gray Cavity theory<sup>8,22</sup>. Thus the clinically approved and treated cases were all specified in terms of absorbed dose to medium, which were then converted to dose to water specification and compared with the treated plan. Minimum segment width assigned was taken to be 0.5 cm. Grid size and calculation accuracy were set to 0.3 cm and 3% percent per control point, respectively.

### 2.3. Plan Analysis

The dose-volume histograms (DVHs) of both the plans calculated for  $D_m$  and  $D_w$  were generated in the Monaco TPS. Treatment plans were evaluated for various dosimetric parameters. The parameters analyzed were Maximum dose  $D_{max}$ , Minimum dose  $D_{min}$ , Mean Dose  $D_{mean}$  for organs at risk and those analyzed for PTVs are  $D_{max}$ ,  $D_{min}$ ,  $D_{mean}$  and percentage volume covered by 95% prescribed dose  $D_{95\%}$ . Cumulative dose volume histogram of one of the patients representing both  $D_m$  and  $D_w$  calculation is shown in figure 1. Ratios of absorbed dose to water to absorbed dose to medium  $D_w/D_m$  were computed for  $D_{max}$ ,  $D_{min}$ ,  $D_{mean}$  and for percentage volume covered by 95% prescribed dose  $D_{95\%}$  (PTVs). The ratios  $D_w/D_m$  were plotted for critical organs at risks and for PTVs.



**Figure 1:** DVHs and isodose distributions of  $D_w$  and  $D_m$  based plans of one of the cases under study.

The relative percentage difference  $\Delta$  between the dosimetric parameters  $D_w$  and  $D_m$  based plans for each case was calculated using the relation

$$\Delta = \left[ \frac{(D_{wx} - D_{mx})}{D_{mx}} \right] \times 100 \%,$$

where  $x$  is the corresponding dosimetric parameter (mean dose, maximum dose, etc.). The mean and the standard deviation of the percentage variations of corresponding dosimetric parameters corresponding to all patient cases were calculated.


### 3. Results

The percentage variation of  $D_w$  with respect to  $D_m$  and the respective standard deviation for all critical organs were obtained as shown in the Table 2. The variations of ratio  $D_w/D_m$  for Maximum dose  $D_{max}$ , Minimum dose  $D_{min}$ ,

Mean Dose  $D_{mean}$  for critical organs at risk are shown in the Figure 2. The mean percentage variation of  $D_{w\ min}$  with respect to  $D_{m\ min}$  for brainstem, spinal cord, left and right lens, left and right parotids, larynx, left & right middle ear and lips were found to be 0.80, 1.13, 0.80, 0.85, -0.43, -0.61, 0.84, 2.23, 2.16, and -0.49, respectively. The corresponding values of  $D_{w\ mean}$  with respect to  $D_{m\ mean}$  for brainstem, spinal cord, left and right lens, left & right parotids, larynx, left and right middle ear and lips were obtained as 0.95, 1.10, 0.77, 0.77, 0.30, 0.30, 0.45, 1.80, 1.86, 1.91 and 0.77, respectively. However, the mean percentage variation of  $D_{w\ max}$  with respect to  $D_{m\ max}$  for brainstem, spinal cord, left and right lens, left and right parotids, larynx, left & right middle ear and lips were found to be 1.06, 1.95, 0.60, 0.61, 0.62, 0.52, 1.24, 4.70, 4.02 and 4.35, respectively. The plots showing the variation of ratio  $D_w/D_m$  for  $D_{max}$ ,  $D_{min}$  and  $D_{mean}$  of critical organs at risk are shown in Figure 2.

**Table 2:** Percentage variation  $\pm$  standard deviation of  $D_w$  with respect to  $D_m$  for critical organs at risk


Organs at risk	$\left[ \frac{(D_{wmin} - D_{mmin})}{D_{mmin}} \right] \times 100 \%$	$\left[ \frac{(D_{wmax} - D_{mmax})}{D_{mmax}} \right] \times 100 \%$	$\left[ \frac{(D_{wmean} - D_{mmean})}{D_{mmean}} \right] \times 100 \%$
Brain stem	$0.80 \pm 0.23$	$1.06 \pm 0.51$	$0.95 \pm 0.07$
Spinal cord	$1.13 \pm 1.16$	$1.95 \pm 1.15$	$1.10 \pm 0.13$
LT lens	$0.80 \pm 0.26$	$0.60 \pm 0.32$	$0.77 \pm 0.29$
RT lens	$0.85 \pm 0.31$	$0.61 \pm 0.35$	$0.77 \pm 0.29$
Parotid LT	$-0.43 \pm 0.64$	$0.62 \pm 0.99$	$0.30 \pm 0.38$
Parotid RT	$-0.61 \pm 0.60$	$0.52 \pm 0.70$	$0.30 \pm 0.39$
Larynx	$0.84 \pm 0.83$	$1.24 \pm 0.82$	$0.45 \pm 0.28$
Middle ear LT	$2.23 \pm 3.47$	$4.70 \pm 2.76$	$1.80 \pm 1.38$
Middle ear RT	$2.16 \pm 3.64$	$4.02 \pm 2.48$	$1.86 \pm 1.43$
Lips	$-0.49 \pm 0.73$	$4.35 \pm 3.32$	$1.91 \pm 1.25$



**Figure 2:** Variations of ratio  $D_w/D_m$  for  $D_{max}$ ,  $D_{min}$ ,  $D_{mean}$  for critical organs at risk.

**Table 3:** Percentage variation  $\pm$  standard deviation of  $D_w$  with respect to  $D_m$  for multiple planning target volumes.

PTVs	$\left[ \frac{(D_{wmin} - D_{min})}{D_{min}} \right] \times 100\%$	$\left[ \frac{(D_{wmax} - D_{max})}{D_{max}} \right] \times 100\%$	$\left[ \frac{(D_{wmean} - D_{mean})}{D_{mean}} \right] \times 100\%$	$\left[ \frac{(V_{95\% Dw} - V_{95\% Dm})}{V_{95\% Dm}} \right] \times 100\%$
PTV I	0.97 $\pm$ 2.01	4.95 $\pm$ 5.29	0.76 $\pm$ 0.37	0.07 $\pm$ 0.20
PTV II	0.61 $\pm$ 1.81	6.37 $\pm$ 4.75	0.88 $\pm$ 0.27	0.48 $\pm$ 0.30
PTV III	-0.35 $\pm$ 1.42	6.38 $\pm$ 4.86	0.49 $\pm$ 0.37	-0.04 $\pm$ 0.20

**Figure 3:** Variations of ratio  $D_w/D_m$  for Maximum dose  $D_{max}$ , Minimum dose  $D_{min}$ , Mean Dose  $D_{mean}$  for multiple PTVs.

The percentage variations of  $D_w$  with respect to  $D_m$  for PTVs are shown in Table 3. The mean percentage variation of  $D_{wmin}$  with respect to  $D_{min}$  for PTV I, PTV II and PTV III were obtained as 0.97, 0.61 and -0.35, respectively; The mean percentage variation of  $D_{wmean}$  with respect to  $D_{mean}$  were found to be 0.76, 0.88 and 0.49 respectively. However, the mean percentage variation of  $D_{wmax}$  with respect to  $D_{max}$  were found to be 4.95, 6.37, and 6.38 respectively. Plots showing the variations of ratio  $D_w/D_m$  for Maximum dose  $D_{max}$ , Minimum dose  $D_{min}$ , Mean Dose  $D_{mean}$  of PTV I, PTV II and PTV III are shown in Figure 3.

#### 4. Discussion

In clinical evaluation and dose calculation methods adopted for radiation therapy treatment plans, it still remains unsettled whether one should consider dose-to-medium  $D_m$  in place of dose-to-water  $D_w$ . There are strong arguments in favor of both. In dosimetry, when using ionization chamber, one measures the charge produced in air then converts the measured charge to dose to water. So, it will be more sensible to convert dosimeter readings and results from dose calculation algorithms to  $D_m$  for comparison with Monte Carlo results. Also, converting  $D_m$  to  $D_w$  might bring additional uncertainty and complexity. However, since dosimetry calibration protocols are based on  $D_w$



standard (AAPM TG-51 1999)<sup>23</sup>, conversion of all dose calculation results to this standard seems reasonable. Furthermore, the biological indices (NTCP, TCP etc.) are given in terms of  $D_w$ . Ma et al.<sup>24</sup> suggested in favor of  $D_m$ -based approach for radiation therapy dose prescription, treatment plan evaluation and plan outcome consistent with previous radiation therapy experience. On the other hand, Walter et al.<sup>25</sup> suggested that the selection of  $D_w$  in place of  $D_m$  in MC treatment plans is more reasonable, since  $D_w$  provides better estimate of dose to sensitive skeletal tissues. The AAPM TG 105 report recommends that in TPS one can avail both the options ( $D_m$  and  $D_w$ ) for dose reporting<sup>1</sup>. Such an approach helps to have a comparative dosimetric analysis leading to appropriate dose prescription in TPS and thus revealing the clinical significance of the method used.

In the present study, it was observed that  $D_{w\ min}$ ,  $D_{w\ mean}$  and volume of  $D_{w\ 95\%}$  for PTVs did not vary much (0.5-2%), whereas  $D_{w\ max}$  varied significantly around 5-7% which may have some biological effect like necrosis in tumor. Since maximum dose escalation may be acceptable in most PTV cases, its variation may not be clinically that significant and may not affect the tumor control. For critical organs at risk, the variation of  $D_{w\ mean}$  for parallel organs like left and right parotids, larynx, left & right middle ear and lips were found to be small (1-2%). But, maximum doses for lips, left and right middle ear in  $D_w$  based calculation were found to differ more than 4%. Since only mean dose is clinically significant for parallel organs, present analysis shows that the choice of  $D_w$  or  $D_m$  based calculation, does not have any significant clinical effect. In case of serial organs like spinal cord and brainstem, the mean percentage variation of  $D_{w\ max}$  with respect to  $D_{m\ max}$  was found less around 1-2%. For Lenses, it was varying only about 0.6%. Hence, it looks like that in plan evaluation and implementation whether one uses  $D_w$  or  $D_m$  based calculations, the clinical endpoint almost remains unaffected. Further studies encompassing larger sample size of patients and more sites may reveal more about the clinical significance of using  $D_w$  or  $D_m$  in such MC based radiation therapy treatment planning systems.

## 5. Conclusion

The present study evaluates the dosimetric differences between  $D_m$  or  $D_w$  based calculations for head & neck VMAT cases in the radiation therapy treatment planning system (Monaco TPS) using the Monte Carlo-based dose calculation algorithms. The analysis of dosimetric parameters indicates that the selection of either  $D_m$  or  $D_w$  based calculations in the Monaco planning system is less likely to produce any significant clinical effect in tumor control and damage to organs at risk. However, there is appreciable increase in the maximum doses calculated based on  $D_w$  compared to  $D_{m\ max}$  in target which may be clinically desirable in PTVs.

## Conflict of interest

The authors declare that they have no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

## References

1. Indrin JC, Curran B, Cygler JE, et al. Report of the AAPM Task Group No. 105: Issues associated with clinical implementation of Monte Carlo-based photon and electron external beam treatment planning. *Med Phys.* 2007;34(12):4818-53.
2. Rogers DWO, Bielajew AF, Kase DK, et al. Monte Carlo techniques of electrons and photons for radiation dosimetry. *Dosimetry of Ionizing Radiation.* 3<sup>rd</sup> ed. New York: Academic;1990:427-539.
3. Mackie TR, Kase DK, Bjarngard BE, et al. Applications of the Monte Carlo method in radiotherapy. *Dosimetry of Ionizing Radiation.* 3<sup>rd</sup> ed. New York: Academic;1990:541-620
4. Andreo P. Monte Carlo techniques in medical radiation physics. *Phys Med Biol.* 1991;36:861-920.
5. Ma CM, Jiang SB. Monte Carlo modelling of electron beams from medical accelerators. *Phys Med Biol.* 1999;44R:157-89.
6. Verhaegen F, Devic S. Sensitivity study for CT image use in Monte Carlo treatment planning. *Phys Med Biol.* 2005;50:937-46.
7. Reynaert N. Monte Carlo treatment planning for photon and electron beams. *Radiat Phys Chem.* 2007;76:643-86.
8. Siebers JV, Keall PJ, Nahum AE, et al. Converting absorbed dose to medium to absorbed dose to water for Monte Carlo based photon beam dose calculations. *Phys Med Biol.* 2000;45:983-95.
9. Huq MS, Andreo P, Song H. Comparison of the IAEA TRS-398 and AAPM TG-51 absorbed dose to water protocols in the dosimetry of high-energy photon and electron beams. *Phys Med Biol.* 2001;46(11):2985-3006.
10. Solberg TD, DeMarco JJ, Holly FE, et al. Monte Carlo treatment planning for stereotactic radiosurgery. *Radiother Oncol.* 1998;49(1):73-84.
11. Li JS, Freedman GM, Price R, et al. Clinical implementation of intensity-modulated tangential beam irradiation for breast cancer. *Med Phys.* 2004;31(5):1023-31.
12. Jin L, Wang L, Li J, et al. Investigation of optimal beam margins for stereotactic radiotherapy of lung-cancer using monte carlo dose calculations. *Phys Med Biol.* 2007;52(12):3549-61.
13. Sterpin E, Salvat F, Cravens R, et al. Monte Carlo simulation of helical tomotherapy with

- PENELOPE. *Phys Med Biol.* 2008;53(12):2161-80.
14. Bush K, Townson R, Zavgorodni S. Monte Carlo simulation of RapidArc radiotherapy delivery. *Phys Med Biol.* 2008;53(19):N359-N70.
  15. Siebers JV, Keall PJ, Kim JO, *et al.* A method for photon beam monte carlomultileaf collimator particle transport. *Phys Med Biol.* 2002;47(17):3225-49.
  16. Du Plessis FC, Willemse CA, Lötter MG, *et al.* The indirect use of ct numbers to establish material properties needed for monte carlo calculation of dose distributions in patients. *Med Phys.* 1998;25(7):1195-201.
  17. Fippel M, Nüsslin F. Comments on 'Converting absorbed dose to medium to absorbed dose to water for monte carlo based photon beam dose calculations'. *Phys Med Biol.* 2007;45(8):L17-9.
  18. Liu HH, Keall P. Dm Rather than Dwshould be used in Monte Carlo treatment planning. For the Proposition. *Med Phys.* 2002;29(5):922-3.
  19. Usmani MN, Masai N, Oh RJ, *et al.* Comparison of absorbed dose to medium and absorbed dose to water for spine IMRT plans using a commercial Monte Carlo treatment planning system. *International Journal of Medical Physics, Clinical Engineering and Radiation Oncology.* 2014;3:60-66.
  20. Rana S, Pokharel S. Dose-to-medium vs. dose-to-water: Dosimetric evaluation of dose reporting modes in Acuros XB for prostate, lung and breast cancer. *Int J Cancer Ther Oncol.* 2014;2(4):020421.
  21. Dogan N, Siebers JV, Keall PJ. Clinical comparison of head and neck and prostate IMRT plans using absorbed dose to medium and absorbed dose to water. *Phys Med Biol.* 2006;51(19):4967-80.
  22. Monaco Training Guide, IMPAC Medical Systems, Inc. Document ID: LTGMON0500
  23. Almond PR, Biggs PJ, Coursey BM, *et al.* AAPM's TG-51 protocol for clinical reference dosimetry of high-energy photon and electron beams. *Med Phys.* 1999;26(9):1847-70.
  24. Ma CM, Li JS. Dose specification for radiation therapy: dose to water or dose to medium. *Phys Med Biol.* 2011;56(10):3073-90.
  25. Walters BR, Kramer R, Kawrakow I. Dose to Medium versus Dose to Water as an estimator of dose to sensitive skeletal tissue. *Phys Med Biol.* 2010;55(16):4535-46.